[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658200":3},{"organization":4,"outcomesModule":7,"designInfo":44,"detailedDescription":11,"studyPopulation":11,"armGroups":50,"interventions":64,"overallOfficials":80,"centralContacts":84,"locations":92,"responsibleParty":319,"collaborators":321,"id":323,"slug":324,"hasResults":325,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":11,"eligibilityCriteria":329,"healthyVolunteers":325,"sex":330,"minAge":331,"maxAge":11,"enrollmentInfo":332,"targetDuration":11,"studyType":335,"phases":336,"briefSummary":338,"conditions":339,"keywords":11,"overallStatus":341,"whyStopped":11,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":351},{"fullName":5,"class":6},"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":21,"otherOutcomes":11},[9,13,15,17,19],{"measure":10,"description":11,"timeFrame":12},"Incidence of adverse events (AEs)",null,"Up to 2 years",{"measure":14,"description":11,"timeFrame":12},"Incidence of serious adverse events (SAEs)",{"measure":16,"description":11,"timeFrame":12},"Incidence of AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria",{"measure":18,"description":11,"timeFrame":12},"Incidence of AEs leading to discontinuation",{"measure":20,"description":11,"timeFrame":12},"Number of deaths",[22,24,26,28,30,32,34,36,38,40,42],{"measure":23,"description":11,"timeFrame":12},"Overall response rate (ORR)",{"measure":25,"description":11,"timeFrame":12},"Complete response rate (CRR)",{"measure":27,"description":11,"timeFrame":12},"Disease control rate (DCR)",{"measure":29,"description":11,"timeFrame":12},"Duration of response (DOR)",{"measure":31,"description":11,"timeFrame":12},"Progression-free survival (PFS)",{"measure":33,"description":11,"timeFrame":12},"Time to response (TTR)per investigator assessed Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause, whichever comes first",{"measure":35,"description":11,"timeFrame":12},"Overall survival (OS)",{"measure":37,"description":11,"timeFrame":12},"Maximum observed concentration (Cmax)",{"measure":39,"description":11,"timeFrame":12},"Time of maximum observed concentration (Tmax)",{"measure":41,"description":11,"timeFrame":12},"Area under the concentration-time curve from time zero to day 28 (AUC(0-28))",{"measure":43,"description":11,"timeFrame":12},"The persistence of BMS-986527 in peripheral blood from pre-dose to post-treatment follow-up",{"allocation":45,"interventionModel":46,"interventionModelDescription":11,"primaryPurpose":47,"observationalModel":11,"timePerspective":11,"maskingInfo":48},"NON_RANDOMIZED","SINGLE_GROUP","TREATMENT",{"masking":49,"maskingDescription":11,"whoMasked":11},"NONE",[51,56,60],{"label":52,"type":53,"description":11,"interventionNames":54},"Cohort 1: BMS-986527 monotherapy","EXPERIMENTAL",[55],"Drug: BMS-986527",{"label":57,"type":53,"description":11,"interventionNames":58},"Cohort 2: BMS-986527 with Nivolumab",[55,59],"Drug: Nivolumab",{"label":61,"type":53,"description":11,"interventionNames":62},"Cohort 3: BMS-986527 with Cabozantinib",[55,63],"Drug: Cabozantinib",[65,70,75],{"type":66,"name":67,"description":68,"armGroupLabels":69,"otherNames":11},"DRUG","BMS-986527","Specified dose on specified days",[52,57,61],{"type":66,"name":71,"description":68,"armGroupLabels":72,"otherNames":73},"Nivolumab",[57],[74],"Opdivo",{"type":66,"name":76,"description":68,"armGroupLabels":77,"otherNames":78},"Cabozantinib",[61],[79],"CABOMETYX",[81],{"name":82,"affiliation":82,"role":83},"Bristol-Myers Squibb","STUDY_DIRECTOR",[85,90],{"name":86,"role":87,"phone":88,"phoneExt":11,"email":89},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":91,"role":87,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[93,109,122,134,147,160,173,188,200,215,227,242,255,270,282,296,310],{"facility":94,"status":11,"city":95,"state":96,"zip":97,"country":98,"countryCode":99,"cosmosGeoPoint":100,"geoPoint":105,"contacts":106},"Local Institution - 0018","New Haven","Connecticut","06510","United States","US",{"type":101,"coordinates":102},"Point",[103,104],-72.92816,41.30815,{"lat":104,"lon":103},[107],{"name":108,"role":87,"phone":11,"phoneExt":11,"email":11},"Site 0018",{"facility":110,"status":11,"city":111,"state":112,"zip":113,"country":98,"countryCode":99,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"Local Institution - 0022","Basking Ridge","New Jersey","07920",{"type":101,"coordinates":115},[116,117],-74.54932,40.70621,{"lat":117,"lon":116},[120],{"name":121,"role":87,"phone":11,"phoneExt":11,"email":11},"Site 0022",{"facility":123,"status":11,"city":124,"state":124,"zip":125,"country":98,"countryCode":99,"cosmosGeoPoint":126,"geoPoint":130,"contacts":131},"Local Institution - 0024","New York","10027",{"type":101,"coordinates":127},[128,129],-74.00597,40.71427,{"lat":129,"lon":128},[132],{"name":133,"role":87,"phone":11,"phoneExt":11,"email":11},"Site 0024",{"facility":135,"status":11,"city":136,"state":137,"zip":138,"country":98,"countryCode":99,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"Local Institution - 0017","Cleveland","Ohio","44195",{"type":101,"coordinates":140},[141,142],-81.69541,41.4995,{"lat":142,"lon":141},[145],{"name":146,"role":87,"phone":11,"phoneExt":11,"email":11},"Site 0017",{"facility":148,"status":11,"city":149,"state":150,"zip":151,"country":98,"countryCode":99,"cosmosGeoPoint":152,"geoPoint":156,"contacts":157},"Local Institution - 0019","Houston","Texas","77030",{"type":101,"coordinates":153},[154,155],-95.36327,29.76328,{"lat":155,"lon":154},[158],{"name":159,"role":87,"phone":11,"phoneExt":11,"email":11},"Site 0019",{"facility":161,"status":11,"city":162,"state":163,"zip":164,"country":98,"countryCode":99,"cosmosGeoPoint":165,"geoPoint":169,"contacts":170},"Local Institution - 0026","Seattle","Washington","98109-1024",{"type":101,"coordinates":166},[167,168],-122.33207,47.60621,{"lat":168,"lon":167},[171],{"name":172,"role":87,"phone":11,"phoneExt":11,"email":11},"Site 0026",{"facility":174,"status":11,"city":175,"state":176,"zip":177,"country":178,"countryCode":179,"cosmosGeoPoint":180,"geoPoint":184,"contacts":185},"Local Institution - 0004","Ghent","Oost-Vlaanderen","9000","Belgium","BE",{"type":101,"coordinates":181},[182,183],3.71667,51.05,{"lat":183,"lon":182},[186],{"name":187,"role":87,"phone":11,"phoneExt":11,"email":11},"Site 0004",{"facility":189,"status":11,"city":190,"state":11,"zip":191,"country":178,"countryCode":179,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"Local Institution - 0003","Leuven","3000",{"type":101,"coordinates":193},[194,195],4.70093,50.87959,{"lat":195,"lon":194},[198],{"name":199,"role":87,"phone":11,"phoneExt":11,"email":11},"Site 0003",{"facility":201,"status":11,"city":202,"state":203,"zip":204,"country":205,"countryCode":206,"cosmosGeoPoint":207,"geoPoint":211,"contacts":212},"Local Institution - 0007","Villejuif","Val-de-Marne","94800","France","FR",{"type":101,"coordinates":208},[209,210],2.35992,48.7939,{"lat":210,"lon":209},[213],{"name":214,"role":87,"phone":11,"phoneExt":11,"email":11},"Site 0007",{"facility":216,"status":11,"city":217,"state":11,"zip":218,"country":205,"countryCode":206,"cosmosGeoPoint":219,"geoPoint":223,"contacts":224},"Local Institution - 0014","Marseille","13273",{"type":101,"coordinates":220},[221,222],5.38107,43.29695,{"lat":222,"lon":221},[225],{"name":226,"role":87,"phone":11,"phoneExt":11,"email":11},"Site 0014",{"facility":228,"status":11,"city":229,"state":230,"zip":231,"country":232,"countryCode":233,"cosmosGeoPoint":234,"geoPoint":238,"contacts":239},"Local Institution - 0005","Essen","North Rhine-Westphalia","45122","Germany","DE",{"type":101,"coordinates":235},[236,237],7.01228,51.45657,{"lat":237,"lon":236},[240],{"name":241,"role":87,"phone":11,"phoneExt":11,"email":11},"Site 0005",{"facility":243,"status":11,"city":244,"state":245,"zip":246,"country":232,"countryCode":233,"cosmosGeoPoint":247,"geoPoint":251,"contacts":252},"Local Institution - 0012","Jena","Thuringia","07747",{"type":101,"coordinates":248},[249,250],11.5899,50.92878,{"lat":250,"lon":249},[253],{"name":254,"role":87,"phone":11,"phoneExt":11,"email":11},"Site 0012",{"facility":256,"status":11,"city":257,"state":258,"zip":259,"country":260,"countryCode":261,"cosmosGeoPoint":262,"geoPoint":266,"contacts":267},"Local Institution - 0010","Rozzano","Milano","20089","Italy","IT",{"type":101,"coordinates":263},[264,265],9.1559,45.38193,{"lat":265,"lon":264},[268],{"name":269,"role":87,"phone":11,"phoneExt":11,"email":11},"Site 0010",{"facility":271,"status":11,"city":272,"state":11,"zip":273,"country":260,"countryCode":261,"cosmosGeoPoint":274,"geoPoint":278,"contacts":279},"Local Institution - 0011","Roma","00168",{"type":101,"coordinates":275},[276,277],11.10642,44.99364,{"lat":277,"lon":276},[280],{"name":281,"role":87,"phone":11,"phoneExt":11,"email":11},"Site 0011",{"facility":283,"status":11,"city":284,"state":11,"zip":285,"country":286,"countryCode":287,"cosmosGeoPoint":288,"geoPoint":292,"contacts":293},"Local Institution - 0008","Amsterdam","1066 CX","Netherlands","NL",{"type":101,"coordinates":289},[290,291],4.88969,52.37403,{"lat":291,"lon":290},[294],{"name":295,"role":87,"phone":11,"phoneExt":11,"email":11},"Site 0008",{"facility":297,"status":11,"city":298,"state":11,"zip":299,"country":300,"countryCode":301,"cosmosGeoPoint":302,"geoPoint":306,"contacts":307},"Local Institution - 0020","Madrid","28040","Spain","ES",{"type":101,"coordinates":303},[304,305],-3.70256,40.4165,{"lat":305,"lon":304},[308],{"name":309,"role":87,"phone":11,"phoneExt":11,"email":11},"Site 0020",{"facility":311,"status":11,"city":298,"state":11,"zip":312,"country":300,"countryCode":301,"cosmosGeoPoint":313,"geoPoint":315,"contacts":316},"Local Institution - 0002","28041",{"type":101,"coordinates":314},[304,305],{"lat":305,"lon":304},[317],{"name":318,"role":87,"phone":11,"phoneExt":11,"email":11},"Site 0002",{"type":320,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[322],{"name":82,"class":6},"100658200","phase-1-a-study-to-assess-the-safety-and-tolerability-of-bms-986527-in-participants-with-clear-cell-renal-cell-carcinoma-ccrcc-100658200",false,"NCT07848295","A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)","A Phase 1, Multicenter, Open-label, Study of BMS-986527, Healthy Donor Allogeneic CD70-targeted Chimeric Antigen Receptor (CAR) T Cells, as Monotherapy or in Novel Combinations in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)","Inclusion Criteria\n\n* Participants must have a histologically confirmed diagnosis of a locally advanced and unresectable or metastatic renal cell carcinoma (RCC) with clear cell component.\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Participants must have measurable disease as assessed by the Investigator using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).\n* For Cohorts 1 and 2, participants should have previously received, be refractory to, ineligible for, or intolerant of standard of care (SoC) immunotherapy (IO) and\u002For tyrosine kinase inhibitors (TKIs). Participants in Cohort 3 should have previously received, be refractory to, ineligible for, or intolerant of SoC IO, but those who have not been previously exposed to SoC TKI agents are permitted.\n\nExclusion Criteria\n\n* Participants must not have prior history of malignancies (other than clear cell renal cell carcinoma (ccRCC)) or lymphoproliferative disease, unless the participant has been free of the disease for ≥ 2 years.\n* For Cohort 2 only: has relapsed or is refractory within 12 months of the most recent IO therapy.\n* For Cohort 3 only: use of strong inhibitor and inducers of CYP3A4, and P-glycoprotein (P-gp) substrates within 14 days or 5 half-lives (whichever is longer) of start of TKI.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","18 Years",{"count":333,"type":334},112,"ESTIMATED","INTERVENTIONAL",[337],"PHASE1","The purpose of this study is to assess the safety and tolerability of BMS-986527 in participants with Clear Cell Renal Cell Carcinoma (ccRCC)",[340],"Clear Cell Renal Cell Carcinoma (ccRCC)","NOT_YET_RECRUITING","2026-09-22",{"date":344,"type":345},"2026-09-30","ACTUAL",{"date":347,"type":334},"2026-12-31",{"date":349,"type":334},"2031-04-17",{"name":5,"class":6},17]